Location History:
- Walnut Creek, CA (US) (2022 - 2023)
- South San Francisco, CA (US) (2022 - 2024)
Company Filing History:
3 out of 71 
1 out of 832,843 Years Active: 2022-2024
Title: Majid Ghoddusi: Innovator in Cancer Treatment
Introduction
Majid Ghoddusi is a prominent inventor based in Walnut Creek, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of antibodies. With a total of 4 patents, Ghoddusi has focused on creating solutions that target specific proteins involved in cancer progression.
Latest Patents
His latest patents include groundbreaking work on B7-H4 antibodies and methods of use. The first patent provides antibodies and antigen-binding fragments that specifically bind to human B7-H4. These anti-B7-H4 antibodies are useful for detecting B7-H4 through immunohistochemistry (IHC). Additionally, the patent outlines methods for treating cancer by administering therapeutic anti-B7-H4 antibodies when increased B7-H4 levels are detected. The second patent also focuses on B7-H4 antibodies, detailing their ability to increase T cell proliferation, enhance interferon-gamma production, and deplete B7-H4 expressing cells via ADCC activity. This patent further emphasizes the potential of these antibodies in treating disorders such as cancer.
Career Highlights
Throughout his career, Majid Ghoddusi has worked with notable companies, including Five Prime Therapeutics, Inc. His work has been instrumental in advancing the understanding and treatment of cancer through innovative antibody therapies.
Collaborations
He has collaborated with esteemed colleagues such as Charles Kaplan and Kathy Miller, contributing to a rich environment of innovation and research.
Conclusion
Majid Ghoddusi's contributions to the field of cancer treatment through his patents on B7-H4 antibodies highlight his role as a key innovator. His work continues to pave the way for new therapeutic approaches in oncology.